BEIJING: China’s Clover Biopharmaceuticals said on Monday (Jun 27) that the booster shot of its COVID-19 vaccine applicant significantly increased antibody response against the Omicron coronavirus variant from levels noticed after two primary shots.
A third dose of its vaccine candidate SCB-2019 resulted in a 19-fold increase in neutralising antibody levels against the Omicron BA. 2 subvariant from pre-booster ranges, Clover said inside a filing to the Hong Kong stock exchange.
The particular booster shot also elicited a 12-fold rise in the neutralising antibody level against the BA. 1 subvariant, the company said, citing preliminary analysis without having providing detailed psychic readings.
The results came from a cohort associated with participants, who got no natural illness of the coronavirus plus showed waning antibodies before the booster, inside a clinical trial which has enrolled 3, 755 participants in Brazilian, the Philippines and Columbia, Clover mentioned.
SCB-2019, which is backed by the Coalition for Epidemic Readiness Innovation (CEPI), offers yet to be accepted for commercial make use of.
Antibody-based readings differ from a vaccine’s efficacy, a rate that will reflects how well it could lower the risk of COVID-19 disease or even death.
Information from a large scientific trial conducted before the spread of Omicron showed SCB-2019 had been 67 per cent effective against symptomatic COVID-19 of any degree of severity and seventy nine per cent against the Delta variant.
Clover did not discuss cell-based responses elicited with the booster, another important section of the human immune system distinctive from antibody-based responses.
Clover is also examining a separate candidate SCB-2020S in an early-stage trial and working on a bivalent vaccine candidate targeting variants of interest including Omicron.
Read more on: https://www.channelnewsasia.com/asia/covid-19-china-clover-booster-lifts-antibody-omicron-2773131
.